^
Association details:
| Biomarker: | ROS1 L2086F |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P12: Activity of gilteritinib in resistant ROS1 rearranged non-small cell lung cancer
Published date:
01/28/2022
Excerpt:
IC50 data summarized in the heatmap shows that ROS1 F2004C, ROS1 G2032R and ROS1 L2086F are entrectinib resistant. Cabozantinib, consistent with our previous published data harbors robust activity against ROS1 G2032R and ROS1 L2086F, however cabozantinib-resistance is imposed by ROS1F2004C mutation. Gilteritinib, intriguingly, is active with IC50 ≤ 25 nM against both ROS1 F2004C and ROS1 L2086F but not ROS1 G2032R.
